Change in BMI ‐ short term (skew) |
Covell 2012 |
Risperidone depot |
1.29 |
1.9 |
23 |
Covell 2012 |
Typical depot antipsychotics |
0.48 |
1.4 |
26 |
Change in BMI ‐ medium term (skew) |
Covell 2012 |
Risperidone depot |
1.53 |
2.2 |
22 |
Covell 2012 |
Typical depot antipsychotics |
0.53 |
1.3 |
24 |
Change in BMI ‐ long term (skew) |
Covell 2012 |
Risperidone depot |
1.04 |
2.0 |
17 |
Covell 2012 |
Typical depot antipsychotics |
‐0.28 |
1.7 |
24 |
Prolactin endpoint levels (ng/mL) ‐ short term (skew) |
Covell 2012 |
Risperidone depot |
22.5 |
19.1 |
19 |
Covell 2012 |
Typical depot antipsychotics |
15.1 |
7.6 |
22 |
Prolactin endpoint levels (ng/mL) ‐ medium term (skew) |
Covell 2012 |
Risperidone depot |
23.4 |
13.8 |
18 |
Covell 2012 |
Typical depot antipsychotics |
16 |
7.5 |
21 |
Prolactin endpoint levels (ng/mL) ‐ long term (skew) |
Covell 2012 |
Risperidone depot |
19 |
10.6 |
14 |
Covell 2012 |
Typical depot antipsychotics |
15.2 |
5.1 |
18 |